Dasatinib: Clinical Trials

10 trials of Dasatinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown, 2 completed, 2 recruiting, 1 active not recruiting. 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 410Unknown 4, Completed 2, Recruiting 2, Active not recruiting 1, Not yet recruiting 1

Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bioequivalence Studies of Dasatinib 100 Mg
Dasatinib 100 MG - Myeloma Multiple
Phase 4Not yet recruitingCentro de Atencion e Investigacion Medica462025-09-012025-02-12
Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight
CEP + Dasatinib + Azacitidine - Angioimmunoblastic T-cell Lymphoma (AITL)
Phase 4Active not recruitingZhengzhou University342023-10-212025-07-01
Asciminib Roll-over Study
Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Phase 4RecruitingNovartis Pharmaceuticals3472022-08-302026-11-09
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
Flumatinib, Dasatinib - Chronic Myeloid Leukemia in Chronic Phase
Phase 4UnknownShenzhen Second People's Hospital1182021-07-012022-07-27
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Dasatinib - Dasatinib, BCR-ABL
Phase 4UnknownShenzhen Second People's Hospital652019-12-012022-07-27
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
Dasatinib Tablets - Chronic Myelogenous Leukemia - Chronic Phase
Phase 4CompletedChia Tai Tianqing Pharmaceutical Group Co., Ltd.622016-05-102021-06-14
Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia
Dasatinib 50 MG - Chronic Myelogenous Leukemia
Phase 4UnknownHospital Universitario Dr. Jose E. Gonzalez122016-04-012017-07-13
Low-dose Chemotherapy Combine With Tyrosine Kinase Inhibitor to Treat ph+ Acute Lymphoblastic Leukemia Patients
Dasatinib, prednisone, dexamethasone - ph+ Acute Lymphoblastic Leukemia
Phase 4UnknownTongji Hospital402016-03-012016-02-24
Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease
Bortezomib, Eltrombopag, Imatinib - Hematological Neoplasms
Phase 4RecruitingWei Zhao15002016-01-312025-03-30
Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib
Dasatinib - Chronic Phase Chronic Myeloid Leukemia
Phase 4CompletedBristol-Myers Squibb392012-12-012016-11-22

Conditions studied

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3)  ·  Leukemia, Myeloid, Chronic-Phase (2)  ·  Blast Crisis (1)  ·  Hematologic Neoplasms (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Multiple Myeloma (1)  ·  Myeloproliferative Disorders (1)

Sponsors

Shenzhen Second People's Hospital (2)  ·  Bristol-Myers Squibb (1)  ·  Centro de Atencion e Investigacion Medica (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Hospital Universitario Dr. Jose E. Gonzalez (1)  ·  Novartis Pharmaceuticals (1)  ·  Tongji Hospital (1)  ·  Wei Zhao (1)  ·  Zhengzhou University (1)

Countries

China (7)  ·  France (2)  ·  Germany (2)  ·  Italy (2)  ·  Mexico (2)  ·  South Korea (2)  ·  United States (2)  ·  Argentina (1)  ·  Austria (1)  ·  Brazil (1)  ·  Bulgaria (1)  ·  Canada (1)  ·  Colombia (1)  ·  Czechia (1)  ·  Denmark (1)

Top investigators

Li Meng, professor (1)  ·  Wei Zhao, Ph.D (1)

Results publications

PMID 24357015, PMID 34240339, PMID 38497347, PMID 38616308

NIH funding

2023 (1)